Posted by Michael Wonder on 02 Nov 2015
Merck receives breakthrough therapy designation from U.S. Food and Drug Administration for Keytruda (pembrolizumab) in advanced colorectal cancer
2 November 2015 - This is the third breakthrough therapy designation granted for Keytruda.
For more details, go to: http://www.mercknewsroom.com/news-release/prescription-medicine-news/merck-receives-breakthrough-therapy-designation-us-food-and-
